Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Shore N, Gazi M, Pieczonka C, Heron S, Modh R, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Bukkapatnam R, Dato P, Bevan-Thomas R, Cornell R, Wise DR, Hardwick MK, Hernandez RD, Rojahn S, Layman P, Hatchell KE, Heald B, Nussbaum RL, Nielsen SM, Esplin ED. Shore N, et al. Among authors: mazzarella b. Eur Urol Oncol. 2023 Oct;6(5):477-483. doi: 10.1016/j.euo.2023.07.008. Epub 2023 Aug 12. Eur Urol Oncol. 2023. PMID: 37574391 Free article.
Reply by Authors.
Kaplan SA, Moss J, Freedman S, Coutinho K, Wu N, Efros M, Elterman D, D'Anna R, Padron O, Robertson KJ, Lawindy S, Mistry S, Shore N, Spier J, Kaminetsky J, Mazzarella B, Cahn D, Jalkut M, Te A. Kaplan SA, et al. Among authors: mazzarella b. J Urol. 2023 Sep;210(3):509. doi: 10.1097/JU.0000000000003568.02. Epub 2023 Jun 21. J Urol. 2023. PMID: 37555602 No abstract available.
The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Kaplan SA, Moss J, Freedman S, Coutinho K, Wu N, Efros M, Elterman D, D'Anna R, Padron O, Robertson KJ, Lawindy S, Mistry S, Shore N, Spier J, Kaminetsky J, Mazzarella B, Cahn D, Jalkut M, Te A. Kaplan SA, et al. Among authors: mazzarella b. J Urol. 2023 Sep;210(3):500-509. doi: 10.1097/JU.0000000000003568. Epub 2023 Aug 9. J Urol. 2023. PMID: 37555604 Clinical Trial.
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Shore N, et al. Among authors: mazzarella b. J Urol. 2024 Dec;212(6):832-843. doi: 10.1097/JU.0000000000004190. Epub 2024 Aug 9. J Urol. 2024. PMID: 39121056
Reply by Authors.
Shore N, Pieczonka C, Heron S, Gazi M, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, Idom C, Morris D, Jayram G, Engelman A, Dato P, Bevan-Thomas R, Wise DR, Hardwick MK, Rojahn S, Layman P, Heald B, Ellsworth RE, Hatchell KE, Nussbaum RL, Nielsen SM, Esplin ED. Shore N, et al. Among authors: mazzarella b. J Urol. 2024 Dec;212(6):842-843. doi: 10.1097/JU.0000000000004221. Epub 2024 Sep 3. J Urol. 2024. PMID: 39226588 No abstract available.
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec.
Narayan VM, Tholomier C, Mokkapati S, Martini A, Caruso VM, Goudarzi M, Mazzarella BC, Phillips KG, Bicocca VT, Levin TG, Yla-Herttuala S, McConkey DJ, Dinney CPN. Narayan VM, et al. Among authors: mazzarella bc. Eur Urol Oncol. 2024 Oct 14:S2588-9311(24)00225-6. doi: 10.1016/j.euo.2024.09.016. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39406613 Free article.
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy.
Rac G, Patel HD, James C, Desai S, Caruso VM, Fischer DS, Lentz PS, Ward CT, Mazzarella BC, Phillips KG, Doshi C, Bicocca VT, Levin TG, Wolfe AJ, Gupta GN. Rac G, et al. Among authors: mazzarella bc. Mol Oncol. 2024 Feb;18(2):291-304. doi: 10.1002/1878-0261.13530. Epub 2023 Oct 5. Mol Oncol. 2024. PMID: 37753732 Free PMC article.
Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
Salari K, Sundi D, Lee JJ, Wu S, Wu CL, DiFiore G, Yan QR, Pienkny A, Lee CK, Oberlin D, Barme G, Piser J, Kahn R, Collins E, Phillips KG, Caruso VM, Goudarzi M, Garcia-Ransom M, Lentz PS, Evans-Holm ME, MacBride AR, Fischer DS, Haddadzadeh IJ, Mazzarella BC, Gray JW, Koppie TM, Bicocca VT, Levin TG, Lotan Y, Feldman AS. Salari K, et al. Among authors: mazzarella bc. Clin Cancer Res. 2023 Sep 15;29(18):3668-3680. doi: 10.1158/1078-0432.CCR-23-0570. Clin Cancer Res. 2023. PMID: 37439796 Free PMC article.
Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention.
Bicocca VT, Phillips KG, Fischer DS, Caruso VM, Goudarzi M, Garcia-Ransom M, Lentz PS, MacBride AR, Jensen BW, Mazzarella BC, Koppie T, Korkola JE, Gray JW, Levin TG. Bicocca VT, et al. Among authors: mazzarella bc. J Clin Med. 2022 Sep 30;11(19):5827. doi: 10.3390/jcm11195827. J Clin Med. 2022. PMID: 36233691 Free PMC article.
95 results